Cleminorexton
Small molecule
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook · registrational
Narcolepsy: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-09-30.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Competitive landscape
This drug's own stage for Narcolepsy: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cleminorexton: this drug | Phase 2/3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav) | Approved | Small molecule | GABA-B receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Modafinil (Provigil) | Approved | Small molecule | Sympathomimetic-like Agent | not yet graded | No reviewed efficacy summary in this indication | |
| Oveporexton (Orzeyful) | Approved | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Approved | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Reliable signal | NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) | |
| Sodium Oxybate | Approved | Small molecule | GABA-B receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | Partial signal | NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results). NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label). | |
| Alixorexton | Phase 3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Reboxetine | Phase 3 | Small molecule | norepinephrine transporter | Partial signal | NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26). | |
| TAK-360 | Phase 2/3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant GR | —(overall) | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cleminorexton to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.